



Pathology/Laboratory and Molecular Pathology/MAAA/GSP CPT® Code Change Applications May 2026 Editorial Panel Meeting

Pathology/Laboratory and Molecular Pathology/MAAA/GSP CPT Code Change Applications (CCAs) that have been submitted for consideration by the CPT Editorial Panel at its May 2026 meeting are listed below. These applications will also be included in the proposed Panel agenda that will be posted to the AMA website on March 6, 2026. This listing includes the code application names, code(s) affected, and a description of the request. **Until such time as the CPT Editorial Panel acts on these requests, the following information is provided for informational purposes only, giving interested individuals the information to help determine whether or not to attend the meeting and provide comment on a given topic(s).**

This listing of Pathology/Laboratory and Molecular Pathology/MAAA/GSP applications is being posted ahead of the full February Panel meeting agenda in order to provide the Molecular Pathology Advisory Group (MPAG) and the Pathology Coding Caucus (PCC) sufficient time to review comments from interested stakeholders prior to making their recommendations to the CPT Editorial Panel.

Codes that contain an 'X' (e.g., 10X24, 23X42, 03X0T) below are temporary codes that are intended to give readers an idea of the proposed placement in the code set of the potential code changes. **These temporary codes are not used for claims reporting and will be removed and not retained when the final CPT Datafiles are distributed on August 31st of each year. To report the services described by the "X" codes listed on this form, please refer to the actual codes as they appear in the CPT Datafiles publication distributed on August 31st of the corresponding year.**

NOTICE –INTERESTED PARTY PROCESS

Upon review of this agenda, if the reviewer believes that they will need to provide comment on an issue, they must seek Interested Party status by [submitting a request](#) for a copy of the application and associated materials. **Requests are to be submitted through the Smart App's CPT Interested Party dashboard.** Those interested in review of the agenda materials are required to complete this form in full.

Any interested parties wishing to provide written comments on any agenda items should be aware of the following relevant deadlines for provision of written comments on the agenda to ensure comment review by all parties. Additional verbal comments on any issue can be provided in person at the Panel meeting following a statement of conflict of interest. The applicant(s) who submitted the original code change application is automatically considered an interested party and is notified by AMA staff of any request for review submitted by another party.

Updated February 27, 2026

- New
- ▲ Revision
- ⊕ Add on
- D Deletion



*Interested party requests will not be processed until the interested party submits a signed confidentiality agreement and disclosure of interest form. Please follow the instructions in the correspondence that accompanies the materials.

Issues	Tabs	Deadline to Request Materials *NEW: you may request materials through Friday of the Panel Meeting.	Comments Deadline (Noon, CST) for Path/Lab
Path/Lab	15-26, 43, 56, 62, 63	-----	March 12, 2026

During the time between now and the Panel meeting, this listing of Pathology/Laboratory and Molecular Pathology/MAAA/GSP CCAs may be modified to reflect changes – additions, deletions or updates. Please check back frequently for the most up to date information. Outcomes on these actions will be listed in the CPT Editorial Panel Summary of Actions for the May 2026 meeting, which will be published on May 15, 2026 to the CPT home page of the AMA website <http://www.ama-assn.org/go/panel-actions>.

	Name	Code #	Request-Description
15	MoPath Tier 1-POLE Gene	●8XX28 ●8XX29	Establish Molecular Pathology Tier 1 codes 8XX28 and 8XX29 for reporting POLE gene analysis.
16	MAAA-Neurology (Multiple Sclerosis)	●8XX25	Establish Category I MAAA code 8XX25 to report algorithmic analysis of 18 protein biomarkers, using antibody-based proteomics technology for multiple sclerosis.

Updated February 27, 2026

- New
- ▲ Revision
- ⊕ Add on
- D Deletion

	Name	Code #	Request-Description
17	MAAA-Oncology (CNS)	● 8XX24 D0020M	Establish Category I MAAA code 8XX24 to report analysis of Central Nervous System Tumor Methylation Classifier (“Classifier”) with specification to the number and type of targets analyzed (ie, add copy number variation analysis [CNV]), and differentiation of artificial intelligence (AI) algorithms and delete Administrative MAAA code 0020M.
18	MAAA-Oncology (Breast)-Revise 81518	▲ 81518	Revise Category I MAAA code 81518 by deleting the term “extended” to allow use for initial and extended treatment periods for endocrine therapy.
19	MAAA-Oncology (Prostate)-Revise 81542	▲ 81542	Revise Category I MAAA code 81542 by removing the term “microarray”.
20	Glial Fibrillary Acidic Protein (GFAP)	● 8XX30	Request to establish 8XX30 to report testing for glial fibrillary acidic protein (GFAP).

	Name	Code #	Request-Description
21	pTau-217/Aβ1-42 Ratio for Alzheimer's Testing	● 8XX26	Establish Category I code 8XX26 for pTau-217 and Aβ1-42 plasma testing performed together with the results expressed as a ratio for analyzing biomarker for Alzheimer's disease.
22	Sexually Transmitted Infection (CV and TV) Test	● 8XX32	Request to establish 8XX32 to report infectious agent detection of <i>Candida species group, Candida glabrata and trichomonas vaginalis</i> using amplified probe technique on nucleic acid (DNA or RNA).
23	Infectious Agent Detection by DNA or RNA-Revise 87800 87801	▲ 87800 ▲ 87801	Revise codes 87800 and 87801 to include "single result" in the code descriptor.
24	Rubeola Virus Molecular Detection, PCR	● 8XX27	Establish code 8XX27 for reporting infectious agent detection by nucleic acid (DNA or RNA), for the rubeola (measles) virus by amplified probe technique

	Name	Code #	Request-Description
25	Pap Test-Digital Dx w Algorithmic Classification	● 8XX31	Request to establish Category I code 8XX31 to report algorithmic segmentation and classification of objects of interest (pap smears) using digital diagnostic selection.
26	Cancer Tissue Selection-Revise 88363	▲ 88363	Revise code 88363 to describe selection of a specimen for AI analysis of bladder cancer prognostic testing.
43	Cat III-Pancreas Chemotherapy Prediction	● X614T	Request to establish Category I code X614T to report augmentative algorithmic analysis of histomorphologic features in digitized slides for preferential response of pancreatic cancer to specified chemotherapy.
56	Cat III-Ex-vivo Profiling-Fresh Tissue	● X649T ● X650T	Establish two Category III codes X649T, X650T to report ex-vivo profiling of fresh tissue sections.

	Name	Code #	Request-Description
62	Cat III-AI Analysis-Slide Images Breast Ca Tissue	● X623T	Establish code X623T to report prognostic assessment of HER2-/HR+ breast cancer using digital pathology enabled, artificial intelligence image analysis.
63	Cat III-AI Analysis-Slide Image Prostate Ca Tissue	● X624T ● X671T	Establish code X624T, X671T to report augmentative analysis of prostate cancer tissue from formalin-fixed paraffin-embedded (FFPE) hematoxylin and eosin (H&E) stained whole-slide images for assessment.